Insights

Strategic Funding Tvardi Therapeutics has secured approximately $81M in funding and recently completed a $28M private placement to support operations through H2 2026, signaling continued capital availability for clinical development and potential collaboration opportunities.

Merger Alignment A pending merger with Cara Therapeutics targeted for close in the first half of 2025 creates potential combined-portfolio opportunities, enabling joint engagements with investors, CROs, and strategic partners interested in broader STAT3-targeted programs.

Clinical-stage Focus As a clinical-stage, small-molecule STAT3 program with an emphasis on inflammatory and proliferative diseases, Tvardi presents partnership avenues for co-development, licensing, and translational research collaborations with mid- to late-stage biotech and pharma companies.

Market Positioning Operating with a lean team and modest revenue, Tvardi may seek alliances with larger players in biopharma that complement STAT3 modalities or expand into related indications, offering scalable collaboration models for milestone-driven deals.

Strategic Partner Fit Similar companies show alignment with mid-sized biotech or specialty pharma partners; prospective sales targets include organizations with multi-indication oncology and inflammatory portfolios, interest in STAT3 pathways, and appetite for private placement-backed collaborations.

Similar companies to Tvardi Therapeutics

Tvardi Therapeutics's Email Address Formats

Tvardi Therapeutics uses at least 1 email format:
Tvardi Therapeutics Email FormatsExamplePercentage
FLast@tvardi.comJDoe@tvardi.com
100%

Frequently Asked Questions

What is Tvardi Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Tvardi Therapeutics's official website is tvardi.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Tvardi Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Tvardi Therapeutics's annual revenue is estimated to be $1M - $10M.

What is Tvardi Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Tvardi Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Tvardi Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Tvardi Therapeutics has approximately 20 employees across 2 continents, including North America and Asia. Key team members include Vice President, Clinical Operations: K. A. R. and Senior Vice President Research And Development: J. L. P. D. Explore Tvardi Therapeutics's employee directory with LeadIQ.

What industry does Tvardi Therapeutics belong to?

Minus sign iconPlus sign icon
Tvardi Therapeutics operates in the Biotechnology Research industry.

What is Tvardi Therapeutics's email format?

Minus sign iconPlus sign icon
Tvardi Therapeutics's email format typically follows the pattern of FLast@tvardi.com. Find more Tvardi Therapeutics email formats with LeadIQ.

How much funding has Tvardi Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Tvardi Therapeutics has raised $81M in funding. The last funding round occurred on Jun 15, 2021 for $72M.

When was Tvardi Therapeutics founded?

Minus sign iconPlus sign icon
Tvardi Therapeutics was founded in 2017.
Tvardi Therapeutics logo

Tvardi Therapeutics

Biotechnology ResearchTexas, United States11-50 Employees

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies that inhibit STAT3, with the aim of treating fibrosis-driven diseases that have significant unmet medical need. STAT3 serves as a central mediator across fibrotic signaling pathways that drive excessive tissue deposition, cell proliferation, survival, and immune suppression, providing rationale for targeting this pathway. The company is evaluating its approach in Phase 2 trials for idiopathic pulmonary fibrosis and hepatocellular carcinoma.

Based in Houston, Texas, Tvardi operates as a small biotechnology organization. In 2025, Tvardi announced a merger with Cara Therapeutics, a development described as progressing toward closing in the first half of the year.

Section iconCompany Overview

Website
tvardi.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $81M

    Tvardi Therapeutics has raised a total of $81M of funding over 2 rounds. Their latest funding round was raised on Jun 15, 2021 in the amount of $72M as a Series B.

  • $1M - $10M

    Tvardi Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.